Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma H-L, Grimm BD, Hulsey ML, McClure HM, McNicholl JM, Moss B, and Robinson HL: Control of a mucosal challenge and prevention of AIDS in rhesus macaques by multiprotein DNA/MVA vaccine. Science Express (online) March 8, 2001 and Science (print version) 292:69-74, 2001. This article was the most cited paper in immunology during the last two months of 2001.
Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, Rizvi TA, Lu S, Hu S-L, Mazzara GP, Panicali DL, Herndon JG, Glickman R, Candido MA, Lydy SL, Wyand MS, and McClure HM: Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat. Med. 5:526-534, 1999. This paper was featured on the 5 year anniversary cover of Nature Medicine.
Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, and Robinson HL: DNA vaccines, protective immunizations by parenteral, mucosal, and gene gun inoculations. Proc. Natl. Acad. Sci. USA 90:11478-11482, 1993. This study was an early pathfinding study for DNA vaccines.
Lu S-H, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink J, Mullins JI, Haynes JR, Letvin NL, Wyand M, and Robinson HL: Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 70:3978-3991, 1996. This study demonstrated that DNA immunizations alone did not elicit protective immunity against a virulent SIV challenge.
Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, Rizvi TA, Lu S, Hu S-L, Mazzara GP, Panicali DL, Herndon JG, Glickman R, Candido MA, Lydy SL, Wyand MS, and McClure HM: Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nature Med. 5:526-534, 1999.
This study demonstrated that DNA priming plus poxvirus boosters were more effective for eliciting protective immunity than DNA priming and protein boosters or DNA priming and boosting. The study also demonstrated that the DNA prime needed to be delivered as a saline injection and not by gene gun. The study demonstrated that the fowlpox virus failed to elicit protective immunity. The study used a non-virulent SHIV challenge.
Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma H-L, Grimm BD, Hulsey ML, McClure HM, McNicholl JM, Moss B, and Robinson HL: Control of a mucosal challenge and prevention of AIDS in rhesus macaques by multiprotein DNA/MVA vaccine. Science Express (online) March 8, 2001 and Science (print version) 292:69-74, 2001.
This study demonstrated that DNA priming and MVA boosting could provide protection against a mucosal challenge administered 7 months after the booster immunization. Both the DNA and MVA immunogens expressed immunodeficiency virus Gag, Pol, and Env proteins, providing a broad target for T cell responses. This vaccine controlled, rather than preventing the challenge infection. This control held for more than 3 years with no escapes. It has also been effective in macaques of diverse histocompatibility types. The study used a virulent SHIV-89.6P challenge.
Amara RR, Smith JM, Staprans SI, Montefiori DC, Montefiori DC, Altman JD, O'Neil SP, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, McNicholl JM, Moss B, and Robinson HL: Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine. J. Virol. 76:6138-6146, 2002.
This study demonstrated that Env as well as Gag and Pol play critical roles in the DNA/MVA vaccine.
Buge SL, Ma H-L, Amara RR, Wyatt LS, Earl PL, Villinger F, Montefiori DC, Staprans SI, Xu Y, O'Neil SP, Herndon JG, Hill E, Moss B, Robinson HL, and McNicholl JM: Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: Higher pre challenge antibody but poorer control of a live viral challenge. AIDS Res. Hum. Retroviruses 19:891-900, 2003.
This study demonstrated that adding gp120 protein boosters to the DNA/MVA regimen decreased rather than increasing protection.
Smith JM, Amara RR, McClure HM, Patel M, Sharma S, Yi H, Chennareddi L, Herndon JG, Butera ST, Heneine W, Ellenberger DL, Parekh B, Earl PL, Wyatt LS, Moss B, and Robinson HL: Multiprotein HIV-1 clade B DNA/MVA vaccine: Construction, safety and immunogenicity. AIDS Res. Hum. Retroviruses AIDS Res Hum Retroviruses 20:1335-47, 2004.
This study presents the first Emory/NIAID HIV vaccine product to go into human trials.
Smith JM, Amara RR, Campbell D, Xu Y, Patel M, Sharma S, Butera ST, Ellenberger DL, Yi H, Chennareddi L, Herndon JG, Wyatt LS, Montefiori DC, Moss B, McClure HM, Robinson HL: DNA/MVA Vaccine for HIV-1: Effects of Codon-Optimization and the Expression of Aggregates or Virus-Like-Particles on the Immunogenicity of the DNA Prime. AIDS Res Hum Retroviruses 20:1335-47, 2004.
This study presents the DNA that will be entered into our 2nd human trial Sadagopal S, Amara RR, Montefiori DC, Wyatt LS, Staprans SI, Kozyr NL, McClure HM, Moss B, Robinson HL: Signature for long-term vaccine-mediated control of a SHIV-89.6P challenge: Stable low breadth and low frequency T cell response capable of co-producing IFN-_ and IL-2. J Virol 79:3243-53, 2005. This study characterizes the T cells mediating long term control of the challenge infection in macaques.
Robinson HL, Ginsberg H, Liu M, Davis H, and Johnston S: The scientific future of DNA for immunization. A position paper for the American Academy of Microbiology. 1997.
Robinson HL: New hope for an AIDS vaccine. Nat. Reviews Immunol. 2:239-250. 2002.
Robinson HL and Amara RR: T cell vaccines for microbial infections. Nat Med online 3/20/05; print 11:S25-32, 2005.